Details

Autor(en) / Beteiligte

• Moreau, Richard
• Durand, Francois
• Poynard, Thierry
• Duhamel, Christian
• Cervoni, Jean-Paul
• Ichaï, Philippe
• Abergel, Armand
• Halimi, Chantal
• Pauwels, Mathieu
• Bronowicki, Jean-Pierre
• Giostra, Emile
• Fleurot, Cathy
• Gurnot, Danielle
• Nouel, Olivier
• Renard, Philippe
• Rivoal, Michel
• Blanc, Pierre
• Coumaros, Dimitri
• Ducloux, Sylvie
• Levy, Stephane
• Pariente, Alexandre
• Perarnau, Jean-Marc
• Roche, Jean
• Scribe-Outtas, Myriam
• Valla, Dominique
• Bernard, Brigitte
• Samuel, Didier
• Butel, Joël
• Hadengue, Antoine
• Platek, Andrzej
• Lebrec, Didier
• Cadranel, Jean-Francois

Titel

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study

Ist Teil von

• Gastroenterology (New York, N.Y. 1943), 2002-04, Vol.122 (4), p.923-930

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2002

Quelle

MEDLINE

Beschreibungen/Notizen

• Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves renal function, its effect on survival is unknown. This study investigated predictive factors of survival in patients with type 1 HRS treated with terlipressin. Ninety-nine patients with type 1 HRS treated with terlipressin in 24 centers were retrospectively studied. Terlipressin-induced improved renal function was defined as a decrease in serum creatinine value to <130 μmol/L or a decrease of at least 20% at the end of treatment. At inclusion, the Child-Pugh score was 11.8 ± 1.6 (mean ± SD). Terlipressin (3.2 ± 1.3 mg/day) was administered for 11 ± 12 days. Renal function improved in 58% of patients (serum creatinine decreased by 46% ± 17% from 272 ± 114 μmol/L). Median survival time was 21 days. Survival rate was 40% at 1 month. Multivariate analysis showed that improved renal function and Child-Pugh score <11 at inclusion were independent predictive factors of survival (P < 0.0001 and 0.02, respectively). Thirteen patients underwent liver transplantation (92 ± 95 days after HRS onset), 10 of whom had received terlipressin and had had improved renal function. This retrospective uncontrolled study shows that in patients with type 1 HRS, terlipressin-induced improved renal function is associated with an increase in survival. Thus, a randomized trial investigating the effect of terlipressin on survival in patients with type 1 HRS should be performed.